After Moderna's Shocking News, Is the Stock a Buy or a Sell?

Moderna held its annual R&D day this week. Moderna's (MRNA -2.01%) struggles may last a little longer than expected. The biotech company had seen both sales and its stock price plummet as demand for its coronavirus vaccine waned, but seemed to be on the road to recovery. It won approval for its new respiratory syncytial virus (RSV) vaccine, reported positive data from trials of late-stage candidates, and even saw its shares climb about 20% in the first half of the year. But Moderna's news hasn't been as bri ...